Clinical Calculator of Conditional Survival Estimates for Resected and Unresected Survivors of Pancreatic Cancer

Overview

Journal Arch Surg

Publisher American Medical Association

Specialty General Surgery

Date 2012 Feb 22

PMID 22351874

Citations 28

Authors

Matthew H G Katz

Chung-Yuan Hu

Jason B Fleming

Peter W T Pisters

Jeffrey E Lee

George J Chang

Affiliations

Soon will be listed here.

Abstract

Objective: To calculate conditional survival estimates for patients with pancreatic adenocarcinoma.

Design: We constructed separate multivariate survival models adjusted for 7 clinicopathologic factors for patients who did and did not undergo radical surgical resection.

Participants: Patients with pancreatic adenocarcinoma diagnosed between 1988 and 2005 included in the Surveillance Epidemiology End Results cancer registry.

Main Outcome Measure: Internet browser-based calculator to compute personalized survival estimates.

Results: Conditional survival probabilities increased over time for all patients with pancreatic cancer regardless of patient characteristics, disease stage, or treatment. For patients with resected stage I, II, or III disease, 3-year conditional cancer-specific survival increased from 38% to 70%, 19% to 54%, and 8% to 39%, respectively, over the 3 years following diagnosis. The relative improvement in survival over time was larger for patients with advanced disease. A customizable, Internet browser-based clinical calculator was implemented that may be used to compute in real time personalized conditional survival estimates based on an individual's unique clinicopathologic profile.

Conclusions: Conditional survival estimates provide a more accurate--and typically more optimistic--assessment of prognosis for patients with pancreatic cancer than traditional survival estimates that apply only at the initial diagnosis.

Citing Articles

Development and Validation of a Survival Prediction Model for Patients With Pancreatic Cancer.

James P, Almousawi F, Salim M, Khan R, Tanuseputro P, Hsu A Clin Transl Gastroenterol. 2024; 16(1):e00774.

PMID: 39620578 PMC: 11756872. DOI: 10.14309/ctg.0000000000000774.

Assessment of intermediate-term mortality following pancreatectomy for cancer.

Janczewski L, Visenio M, Joung R, Yang A, Odell D, Danielson E J Natl Cancer Inst. 2024; 117(1):49-57.

PMID: 39212612 PMC: 11717425. DOI: 10.1093/jnci/djae215.

Early detection of pancreatic cancer.

Morera-Ocon F World J Clin Cases. 2024; 12(17):2935-2938.

PMID: 38898835 PMC: 11185363. DOI: 10.12998/wjcc.v12.i17.2935.

Conditional Relative Survival of Exocrine Pancreatic Cancer: A Population-Based Study.

Kang M, Ha J, Park H, Park S, Jung K, Han S Ann Surg Oncol. 2023; 31(2):1178-1189.

PMID: 38032467 DOI: 10.1245/s10434-023-14594-x.

Pancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening.

Badheeb M, Abdelrahim A, Esmail A, Umoru G, Abboud K, Al-Najjar E Curr Oncol. 2022; 29(11):8693-8719.

PMID: 36421339 PMC: 9689647. DOI: 10.3390/curroncol29110686.

References

Bilimoria K, Bentrem D, Ko C, Stewart A, Winchester D, Talamonti M . National failure to operate on early stage pancreatic cancer. Ann Surg. 2007; 246(2):173-80. PMC: 1933550. DOI: 10.1097/SLA.0b013e3180691579. View

Chang G, Hu C, Eng C, Skibber J, Rodriguez-Bigas M . Practical application of a calculator for conditional survival in colon cancer. J Clin Oncol. 2009; 27(35):5938-43. PMC: 6669907. DOI: 10.1200/JCO.2009.23.1860. View

Riall T, Nealon W, Goodwin J, Zhang D, Kuo Y, Townsend Jr C . Pancreatic cancer in the general population: Improvements in survival over the last decade. J Gastrointest Surg. 2006; 10(9):1212-23. DOI: 10.1016/j.gassur.2006.08.010. View

Kalser M, Ellenberg S . Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985; 120(8):899-903. DOI: 10.1001/archsurg.1985.01390320023003. View

Wang S, Emery R, Fuller C, Kim J, Sittig D, Thomas C . Conditional survival in gastric cancer: a SEER database analysis. Gastric Cancer. 2007; 10(3):153-8. DOI: 10.1007/s10120-007-0424-9. View

Neoptolemos J, Stocken D, Friess H, Bassi C, Dunn J, Hickey H . A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004; 350(12):1200-10. DOI: 10.1056/NEJMoa032295. View

Mehta S, Lubeck D, Pasta D, Litwin M . Fear of cancer recurrence in patients undergoing definitive treatment for prostate cancer: results from CaPSURE. J Urol. 2003; 170(5):1931-3. DOI: 10.1097/01.ju.0000091993.73842.9b. View

Henson D, Ries L, Carriaga M . Conditional survival of 56,268 patients with breast cancer. Cancer. 1995; 76(2):237-42. DOI: 10.1002/1097-0142(19950715)76:2<237::aid-cncr2820760213>3.0.co;2-j. View

Herschbach P, Keller M, Knight L, Brandl T, Huber B, Henrich G . Psychological problems of cancer patients: a cancer distress screening with a cancer-specific questionnaire. Br J Cancer. 2004; 91(3):504-11. PMC: 2409853. DOI: 10.1038/sj.bjc.6601986. View

10.

Xing Y, Chang G, Hu C, Askew R, Ross M, Gershenwald J . Conditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysis. Cancer. 2010; 116(9):2234-41. PMC: 2860044. DOI: 10.1002/cncr.24966. View

11.

Mellon S, Kershaw T, Northouse L, Freeman-Gibb L . A family-based model to predict fear of recurrence for cancer survivors and their caregivers. Psychooncology. 2006; 16(3):214-23. DOI: 10.1002/pon.1074. View

12.

Katz M, Hwang R, Fleming J, Evans D . Tumor-node-metastasis staging of pancreatic adenocarcinoma. CA Cancer J Clin. 2008; 58(2):111-25. DOI: 10.3322/CA.2007.0012. View

13.

Howard T, Krug J, Yu J, Zyromski N, Schmidt C, Jacobson L . A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon's contribution to long-term survival in pancreatic cancer. J Gastrointest Surg. 2006; 10(10):1338-45. DOI: 10.1016/j.gassur.2006.09.008. View

14.

Gleisner A, Assumpcao L, Cameron J, Wolfgang C, Choti M, Herman J . Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified?. Cancer. 2007; 110(11):2484-92. DOI: 10.1002/cncr.23074. View

15.

Herman J, Swartz M, Hsu C, Winter J, Pawlik T, Sugar E . Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol. 2008; 26(21):3503-10. PMC: 3558690. DOI: 10.1200/JCO.2007.15.8469. View

16.

Ferrone C, Brennan M, Gonen M, Coit D, Fong Y, Chung S . Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg. 2007; 12(4):701-6. DOI: 10.1007/s11605-007-0384-8. View

17.

Brennan M, Kattan M, Klimstra D, Conlon K . Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg. 2004; 240(2):293-8. PMC: 1356406. DOI: 10.1097/01.sla.0000133125.85489.07. View

18.

Vickberg S . The Concerns About Recurrence Scale (CARS): a systematic measure of women's fears about the possibility of breast cancer recurrence. Ann Behav Med. 2003; 25(1):16-24. DOI: 10.1207/S15324796ABM2501_03. View

19.

Henson D, Ries L . On the estimation of survival. Semin Surg Oncol. 1994; 10(1):2-6. DOI: 10.1002/ssu.2980100103. View

20.

Wang S, Wissel A, Luh J, Fuller C, Kalpathy-Cramer J, Thomas Jr C . An interactive tool for individualized estimation of conditional survival in rectal cancer. Ann Surg Oncol. 2011; 18(6):1547-52. PMC: 3156394. DOI: 10.1245/s10434-010-1512-3. View